MUC1 and non-small cell lung carcinoma: IgM and IgG anti-MUC1 antibodies have been identified in patients with various adenocarcinomas, and their presence has been associated with better prognosis in breast cancer (101), colorectal cancer (102), non-small cell lung cancer (103), and pancreatic cancer (104).